Skip to main content

Table 4 Numbers of the questions from patients regarding DAAs treatment

From: Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis

Type of questions Number (%)
Adverse drug events 577 (53.8%)
Drug interaction a 205 (19.1%)
Management in the event of a missed dose of DAAs 57 ( 5.3%)
Others 233 (21.8%)
TOTAL 1,072 (100%)
  1. DAAs Direct-acting antivirals
  2. a These included questions according to drug-drug (152 cases), drug-supplement (32 cases), and drug-food (21 cases) interactions